InnoCan PharmaHAM:IP40 +6.19%62 Days Payable is 44.43 as of Mar. 2026, which is 1% above its 10-year median of 43.79. GuruFocus rates HAM:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,882 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 71.52% on this metric.
The historical rank and industry rank for InnoCan Pharma's Days Payable or its related term are showing as below:
HAM:IP40'
s Days Payable Range Over the Past 10 Years
Min: 16.32 Med: 43.79 Max: 21626.25
Current: 28.99
During the past 8 years, InnoCan Pharma's highest Days Payable was 21626.25. The lowest was 16.32. And the median was 43.79.
HAM:IP40's Days Payable is ranked worse than 71.52% of 1882
companies
in the Consumer Packaged Goods industry
Industry Median: 44.145
vs HAM:IP40: 28.99
InnoCan Pharma's Days Payable
increased
from Mar. 2025 (24.77) to Mar. 2026 (44.43).
It may suggest that InnoCan Pharmadelayed paying its suppliers.
InnoCan Pharma Days Payable Related Terms
InnoCan Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
InnoCan Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Days Payable of 44.43 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InnoCan Pharma and its competitors. This is near median its historical median of 43.79. Over the past decade, InnoCan Pharma's Days Payable has ranged from 16.32 to 21,626.25. According to the industry distribution chart, InnoCan Pharma ranks #1346 out of 1882 companies in the Consumer Packaged Goods industry, placing it in the top 71.5%.
Is InnoCan Pharma's Days Payable too high?
InnoCan Pharma's current Days Payable of 44.43 is near median its 10-year median of 43.79. Over the past 10 years, this metric has ranged from a low of 16.32 to a high of 21,626.25. The Consumer Packaged Goods industry median Days Payable is 44.15. InnoCan Pharma's value of 44.43 is 0.6% above this industry median. Based on the distribution chart, InnoCan Pharma ranks #1346 out of 1882 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Days Payable compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1346 out of 1882 companies for Days Payable. This places InnoCan Pharma in the lower half of its industry. The industry median Days Payable is 44.15. InnoCan Pharma's value of 44.43 is 0.6% above this benchmark. Historically, InnoCan Pharma's own Days Payable has ranged from 16.32 to 21,626.25 over the past decade. While the company's 10-year median is 43.79 vs. the industry median of 44.15, InnoCan Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 44.15, based on 1,882 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Days Payable of 44.43 is 0.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 44.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Days Payable is 44.43, which is near median its own 10-year median of 43.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.63 — trading 83.1% below its estimated fair value. The current Days Payable is 44.43, which is near median its 10-year median of 43.79 and 0.6% above the Consumer Packaged Goods industry median of 44.15. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Days Payable is 44.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Days Payable: 44.43 (near median its 10-year median of 43.79)
GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
Industry Position: 0.6% above the Consumer Packaged Goods median (#1346 of 1882)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for HAM:IP40
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
